HDAC6-specific inhibitors (Tubastatin A and Nexturastat) suppress melanoma cell proliferation by increasing the expression levels of tumor-associated antigens (TAAs) and human leukocyte antigen (HLA) class I (Woan et al., 2015). The gene discussed is HDAC6; the disease is melanoma.